Theriva biologics reports third quarter 2022 operational highlights and financial results

–reported encouraging clinical data supporting the differentiated mode-of action of theriva's novel oncolytic adenovirus (ov) platform–

TOVX Ratings Summary

TOVX Quant Ranking